Literature DB >> 12720525

Managing patients with "treatment-resistant" schizophrenia.

Christos Pantelis1, Timothy J R Lambert.   

Abstract

Patients who fail to respond adequately to pharmacological treatment present an ongoing therapeutic challenge. The term "incomplete recovery" (IR) is preferred to the current term "treatment resistance" to describe these patients. IR should be considered from a multidimensional perspective that includes a broad range of symptoms and functional disabilities that are relevant to schizophrenia. The approach to the incompletely recovered patient needs to be systematic, with consideration given to the factors that may hamper recovery. "Atypical" (second-generation) antipsychotic drugs target various domains of symptoms relevant to IR. Adjunctive treatment strategies (eg, mood stabilisers, antidepressants, combinations of antipsychotics) may be useful, but should be undertaken in specialist psychiatric settings. Although pharmacological treatment is a necessary first step in managing incompletely recovered patients, adjunctive psychosocial interventions are needed to optimise treatment success.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720525     DOI: 10.5694/j.1326-5377.2003.tb05310.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  A Prospective Surveillance of Pharmacovigilance of Psychotropic Medicines in a Developing Country.

Authors:  Jisha Myalil Lucca; Madhan Ramesh; Gurumurthy Parthasarathi; Dushad Ram
Journal:  Psychopharmacol Bull       Date:  2016-03-01

Review 2.  The impact of subjective well-being under neuroleptic treatment on compliance and remission.

Authors:  Walter de Millas; Martin Lambert; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

3.  Functional hallucinations in schizophrenia responding to adjunctive sodium valproate.

Authors:  Ravi Philip Rajkumar
Journal:  Indian J Psychol Med       Date:  2012-01

Review 4.  Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia.

Authors:  Viacheslav Terevnikov; Grigori Joffe; Jan-Henry Stenberg
Journal:  Int J Neuropsychopharmacol       Date:  2015-05-19       Impact factor: 5.176

5.  Electroconvulsive Therapy in Functional Hallucination: Scope and Challenges.

Authors:  Sulochana Joshi; Rabi Shakya
Journal:  Case Rep Psychiatry       Date:  2017-10-17

Review 6.  A Synthetic Literature Review on the Management of Emerging Treatment Resistance in First Episode Psychosis: Can We Move towards Precision Intervention and Individualised Care?

Authors:  Siân Lowri Griffiths; Max Birchwood
Journal:  Medicina (Kaunas)       Date:  2020-11-24       Impact factor: 2.430

7.  Pharmacovigilance for psychiatrists: An introduction.

Authors:  Ravi Philip Rajkumar; George Melvin
Journal:  Indian J Psychiatry       Date:  2014-04       Impact factor: 1.759

8.  Magnetic Seizure Therapy in Treatment-Resistant Schizophrenia: A Pilot Study.

Authors:  Victor M Tang; Daniel M Blumberger; Shawn M McClintock; Tyler S Kaster; Tarek K Rajji; Jonathan Downar; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  Front Psychiatry       Date:  2018-01-16       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.